About Cantargia Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform.
More information about Cantargia is available at www.cantargia.com. About CAN04 The antibody CAN04 binds strongly to the target IL1RAP and functions both though ADCC as well as blocking IL-1α and
2021-03-19 · Om Cantargia Cantargia AB (publ), org. nr 556791-6019, är ett bioteknikbolag som utvecklar antikroppsbaserade behandlingar för livshotande sjukdomar. Utgångspunkten är proteinet IL1RAP som är involverat i ett flertal sjukdomar och där Cantargia etablerat en plattform. Om Cantargia. Cantargia AB (publ), reg.no. 556791-6019, är ett bioteknikbolag som utvecklar antikroppsbaserade behandlingar för livshotande sjukdomar. Den ursprungliga upptäckten från forskargruppen bakom Cantargia var ett överuttryck av en specifik målmolekyl, interleukin 1 receptor accessory protein “IL1RAP”, i leukemistamceller.
- Ambulans malmö nummer
- Aktier peptonic medical
- Vad är förskollärarens uppgift
- Dow jones nu
- Tv ikea besta burs
- Stylist kurs stockholm
- Bäckagårdsskolan halmstad rektor
Cantargia AB meddelade idag att dess forskningsplattform CANxx har avancerat genom starten av CAN10 som utvecklingsprojekt. Projektet utgår från hämning av tre inflammatoriska cytokinsystem (IL-1, IL-33 och IL-36) via en antikropp riktad mot målmolekylen interleukin 1 receptor accessory protein (IL1RAP). Cantargia AB meddelade idag uppdaterade interimsresultat från den pågående kliniska studien med antikroppen CAN04, som blockerar interleukin-1 receptor accessory protein (IL1RAP), i kombination Cantargia meddelar att det kinesiska patentverket har utfärdat ett formellt patentgodkännande avseende bolagets ansökan kring IL1RAP som målmolekyl för antikroppsterapi av flera typer av solida tumörer. Cantargia Acquires Cellerant IP on IL1RAP. PRESS RELEASE PR Newswire .
556791-6019, är ett bioteknikbolag som utvecklar antikroppsbaserade behandlingar för livshotande sjukdomar. Den ursprungliga upptäckten från forskargruppen bakom Cantargia var ett överuttryck av en specifik målmolekyl, interleukin 1 receptor accessory protein “IL1RAP”, i leukemistamceller.
IL1RAP is overexpressed on candidate AML stem cells and is a promising target for Cantargia AB is the owner of the intellectual property rights for agents
Den ursprungliga upptäckten från forskargruppen bakom Cantargia var ett överuttryck av en specifik målmolekyl, interleukin 1 receptor accessory protein “IL1RAP”, i leukemistamceller. Cantargia AB (”Cantargia”) meddelar att det kinesiska patentverket State Intellectual Property Office (”SIPO”) har utfärdat ett formellt patentgodkännande avseende bolagets ansökan kring IL1RAP som målmolekyl för antikroppsterapi av flera typer av solida tumörer.
Cantargia meddelar att det kinesiska patentverket har utfärdat ett formellt patentgodkännande avseende bolagets ansökan kring IL1RAP som målmolekyl för antikroppsterapi av flera typer av solida tumörer.
About Cantargia. Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases.
It is developing two antibodies against IL1RAP, nidanilimab (CAN04) and CANxx. Nidanilimab is being studied in a Phase I/II CANFOUR in solid tumours focusing on NSCLC and pancreatic cancer. 2019-12-11
LUND, Sweden I April 7, 2020 I Cantargia AB today announced that the application for a US IND regarding the antibody CAN04 has been submitted to the US FDA. CAN04, an antibody targeting interleukin 1 receptor accessory protein (IL1RAP), is currently being investigated for treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC) in phase IIa clinical development in Europe. Om Cantargia Cantargia AB (publ), org. nr 556791-6019, är ett bioteknikbolag som utvecklar antikroppsbaserade behandlingar för livshotande sjukdomar. Utgångspunkten är proteinet IL1RAP som är involverat i ett flertal sjukdomar och där Cantargia etablerat en plattform. Cantargia AB | 961 followers on LinkedIn.
Diskare jobb malmö
It is developing two antibodies against IL1RAP, nidanilimab (CAN04) and CANxx.
Pancreatic Ductal.
Masterprogram i statsvetenskap
Om Cantargia Cantargia AB (publ), org. nr 556791-6019, är ett bioteknikbolag som utvecklar antikroppsbaserade behandlingar för livshotande sjukdomar. Utgångspunkten är proteinet IL1RAP som är involverat i ett flertal sjukdomar och där Cantargia etablerat en plattform.
A Swedish listed biotechnology company | Cantargia develops antibody based therapy against the target IL1RAP. The lead candidate CAN04 is for treatment of 2020-04-07 Cantargia AB today announced the submission of a clinical trial application investigating antibody CAN04 in combination with FOLFIRINOX for first line treatment of metastatic pancreatic cancer (PDAC). Cantargia is developing the humanised antibody CAN04, against the target molecule Interleukin-1 Receptor Associated Protein ("IL1RAP"), for treatment of cancer. Cantargia has previously shown that Cantargia has announced that its research platform CANxx has progressed with the start of a drug development project, CAN10. The project originates from inhibition of three inflammatory cytokine systems (IL-1, IL-33 and IL-36) by antibody targeting of interleukin 1 receptor accessory protein (IL1RAP). An opposition has been filed against one of the European patents in Cantargia’s patent family covering antibody therapy in solid tumors.
About Cantargia Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform.
January, 2022.
15 Mar 2021 It is developing two assets against IL1RAP, CAN04 and CAN10. The lead clinical trial is a Phase IIa CANFOUR study with CAN04 in non-small IL1RAP is overexpressed on candidate AML stem cells and is a promising target for Cantargia AB is the owner of the intellectual property rights for agents M.J. and T.F. are cofounders and have equity ownership in Cantargia AB (Ideon To study the expression of LSC markers in more detail, IL1RAP, CD25 and. 2 Jun 2019 Cantargia $CANTA CAN04 (anti-IL1RAP) phase I #ASCO19 1/4 good safety profile. 0% ORR/ 43% CBR for the dose-escalation monotherapy CAN04 is a first-in-class fully humanized monoclonal antibody targeting IL1RAP, a co-receptor for the IL-1 receptor which is expressed on human cancer cells. 20 Oct 2016 In the new study Cantargia shows that high levels of IL1RAP are expressed also in several different solid tumours, including non-small cell lung 9 May 2018 antibody attaches to the IL1RAP receptor molecule and blocks it from Cantargia's lead candidate CAN04 targets the IL1RAP molecule and 15 Dec 2020 The basis for this is the protein IL1RAP that is involved in a number of diseases Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). 2 May 2013 Cantargia AB is the owner of the intellectual property rights for agents targeting IL1RAP for use in the treatment and diagnosis of neoplastic 20 Oct 2018 Positive Phase I Clinical Data Presented for Cantargia's Nidanilimab targeting the Interleukin 1 Receptor Accessory Protein (IL1RAP), which 26 May 2019 2504Background: Interleukin 1 receptor Accessory protein, IL1RAP, is expressed in several solid tumors, both on cancer cells and 1 Feb 2021 Cantargia develops IL1RAP-targeting antibodies for treatment of cancer and inflammation and has reached clinical phase II in non-small cell 20 Aug 2020 Cantargia AB. September,. 2020.